Trastuzumab administration during pregnancy: an update

BACKGROUND: Over than one third (28–58%) of pregnancy-associated breast cancer (PABC) cases are characterized by positive epidermal growth factor receptor 2-positive (HER2) expression. Trastuzumab anti-HER2 monoclonal antibody is still the benchmark treatment of HER2-positive breast tumors. However,...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:BMC Cancer
Prif Awduron: Andrikopoulou, Angeliki, Apostolidou, Kleoniki, Chatzinikolaou, Spyridoula, Bletsa, Garyfalia, Zografos, Eleni, Dimopoulos, Meletios-Athanasios, Zagouri, Flora
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2021
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8074427/
https://ncbi.nlm.nih.gov/pubmed/33902516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08162-3
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg